Follow-on Offering

Healthcare
Follow-on Offering

Summary

Baird served as a co-manager on this offering

About

Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) recently completed a follow-on offering of 3,737,500 common shares, including 487,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price of $31.00 per share, generating gross proceeds of approximately $116 million. Reata intends to use the net proceeds from the offering for working capital and general corporate purposes, which include advancing the development of bardoxolone methyl through a Phase 2/3 program in CKD caused by Alport syndrome, Phase 2 programs in additional renal indications, and Phase 2 programs in PH-ILD and the development of omaveloxolone in Friedreich’s ataxia and mitochondrial myopathies.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. The Company’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Reata is headquartered in Irving, Texas.
CONTACT US TO LEARN MORE
Healthcare
Follow-on Offering
Date
August 2017
Company
Reata Pharmaceuticals, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America
Acquiror Location
North America

Share